[Source France 3 Régions]: Lung cancer is one of the most common and also one of the deadliest. In some patients, the combination of chemotherapy and immunotherapy, although effective, does not work. At the Georges François Leclerc centre in Dijon, an Inserm team is studying resistance to chemotherapy of tumour cells to modify their mechanisms. Research that earned him at the end of June an endowment of 75,000 euros by the Amgen Foundation to accelerate his work and find the treatment that will improve the chances of healing patients. The first human clinical trials could begin in 2022. Hope for the sick. Lung cancer causes more than 30,000 deaths each year.
Accessible rights for all uses, in the whole world, in accordance with our T&Cs.
Digital Publication : use for editorial publications - to inform the general public or illustrate the news - for digital broadcast on services, valid for 5 years.
Corporate/Brand content : use for the presentation and promotion of an image, brand, history and values of the Contracting Partner company - or, where applicable, the Beneficiary - for digital broadcast on its services and/or for Events, valid for 1 year.
Cultural Licence : use for cultural purposes and restricted to members of the cultural network. Digital publication for a term of 5 (years) and Events for a term of 1 (one) year from the order payment date.
The INA Galaxy 
Back
